Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview

Date

08 Oct 2016

Session

Poster Display

Presenters

Lisa Salvatore

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

L. Salvatore1, M. Niger2, L. Bellu3, E. Tamburini4, P. Garcia-Alfonso5, N. Amellal6, A. Delmas6, M. Wahba7, G. Prager8

Author affiliations

  • 1 U.o. Oncologia Medica 2 Universitaria, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 2 Medicina Oncologica, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 3 Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 4 Oncologia Medica, Ospedale Infermi, Rimini/IT
  • 5 Department Of Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 6 Oncology Itp, Institut de Recherches Internationales SERVIER (I.R.I.S.), 92284 - SURESNES/FR
  • 7 Medical Affairs, Taiho Oncology, 08822 - Flemington/US
  • 8 Department Of Medicine I, Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT
More

Resources

Abstract 2959

Background

Compassionate use programs (CUPs) provide a treatment option for appropriate patients with unmet medical needs. We describe the trifluridine/tipiracil (TAS-102) CUP set up prior to marketing authorization for management of pretreated metastatic colorectal cancer (mCRC) in countries outside the USA and Japan.

Methods

Registration gave mCRC patients (pts) early access to 2 cycles of treatment, renewable as necessary. Pts' characteristics were collected at registration.

Results

A total of 879 pts were registered in 21 countries by the 1st April 2016 cutoff (Argentina, Brazil, Australia, Austria, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Spain, The Netherlands, Portugal, Romania, South Africa, Switzerland, and UK). Of these, 725 pts (83%) were shipped enough treatment for the first 2 cycles. Mean age was 64 years and 60% were male. Oral trifluridine/tipiracil was initiated at 35 mg/m2 bid. Most pts had received 2, 3, or ≥4 lines of prior treatment for metastatic disease (28%, 32%, and 32%, respectively); 4% had received 1 line of treatment and 4% unknown. The main reasons for not initiating treatment included cancellation of request due to worsening condition and progressive disease. 37 pts (4%) permanently discontinued treatment before the end of cycle 1 or 2 due to disease progression (19 pts), death (8 pts), or other reasons (10 pts). A total of 184 pts (25% of pts in cycles 1or 2) went on to receive trifluridine/tipiracil for cycles 3 or 4. Of those, 28 pts had a dose reduction due to neutropenia (17 pts), diarrhea (3 pts), or other adverse events (8 pts; vomiting, dyspnea, creatinine increase, bowel obstruction, pleural effusion). 24 pts (3%) had treatment permanently discontinued before end of cycles 3or 4 due to progressive disease. 20 pts went on to receive treatment in cycles 5 or 6, 16 pts with no dose reduction.

Conclusions

Real-world treatment and safety data are consistent with those reported in phase 3 trials of trifluridine/tipiracil in pretreated mCRC.

Clinical trial identification

Legal entity responsible for the study

IRIS

Funding

IRIS

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings